PAVMEDLOGONEW15OCT2018.png
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 08, 2021 10:53 ET | PAVmed Inc.
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update
August 18, 2020 16:14 ET | PAVmed Inc.
Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated,...
Neovasc_Logo-web-header.jpg
Neovasc Announces Partial Prepayment of Convertible Debenture
August 17, 2020 09:00 ET | Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that Strul Medical Group LLC (“SMG”)...
Neovasc_Logo-web-header.jpg
Neovasc Announces US$12.6 Million Registered Direct Offering Priced At-the-Market
August 10, 2020 08:00 ET | Neovasc, Inc.
VANCOUVER, CANADA, Aug. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive...
PAVMEDLOGONEW15OCT2018.png
PAVmed to Hold Business Update Conference Call on May 21, 2020
May 11, 2020 09:30 ET | PAVmed Inc.
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
Neovasc_Logo-web-header.jpg
Neovasc Announces Receipt of Nasdaq Extension to Satisfy Market Cap Rule
May 01, 2020 17:00 ET | Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, May 01, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive...
PAVMEDLOGONEW15OCT2018.png
PAVmed Subsidiary Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award
April 02, 2020 09:30 ET | PAVmed Inc.
NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVMEDLOGONEW15OCT2018.png
PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing
March 31, 2020 09:30 ET | PAVmed Inc.
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has...
PAVMEDLOGONEW15OCT2018.png
PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device
March 09, 2020 09:30 ET | PAVmed Inc.
Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq:...
PAVMEDLOGONEW15OCT2018.png
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
March 02, 2020 09:30 ET | PAVmed Inc.
Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and...